Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy

NCT00848081 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00848081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00848081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
December 31, 2009
Enrollment
318 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia